CD4 and neoplasm: On the contrary, P2X7 pharmacological blockade in the P2X7 WT host supports a tumor-aggressive infiltrate characterized by a high number of CD4+ effector T lymphocytes (Teff), reduced expression of OX40 on Tregs and of CD39 and CD73 on Teff, and conventional dendritic cells (cDCs).